ProPhase Labs

PRPH

Medical - Pharmaceuticals · Healthcare

Price

$0.02

-0.01 (-33.33%)

Market Cap

$280,324

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+361.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 1.8M (2021) → 8.5M (2025)

Winston Score History

The full picture

ProPhase Labs is a small healthcare company that makes over-the-counter health products and runs diagnostic testing services. Its best-known product is Cold-EEZE, a zinc-based cold remedy sold in pharmacies and retail stores across the United States. The company also operates a genomics and diagnostics division that offers COVID-19 testing and genetic sequencing services to healthcare providers and consumers.

ProPhase earns money by selling consumer health products at retail and by charging fees for laboratory testing and genomic analysis services. It operates primarily in the United States and is a very small company with a market cap near zero, reflecting serious financial strain. The operating margin of negative 415% signals the company is spending far more than it earns, and the key risk is whether it can stabilize its diagnostics business — which surged during the pandemic but has since seen demand fall sharply — before it runs out of runway to fund operations.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-18.9% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+80.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$107,000/ year

↓ Declining (-82% vs prior year)

2.5% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

8.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

5+ years

Quarterly Free Cash Flow

↑ Burn rate improving

$43M cash & investments at current burn rate

Revenue declining

ProPhase Labs's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

22.4%

Thin — 22.4% gross margin

Profit after running costs

Operating Margin

-261.6%

Losing money on operations — -261.6%

Return on the money invested

ROCE

-44.6%

Weak — -44.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-5.5%

Shrinking sales (-5.5% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-974.8%

Burning cash (-974.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial